Chemotherapy News and Research

Latest Chemotherapy News and Research

Erbitux can now be used in Japan as 1st-line treatment for mCRC: Merck Serono

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced today that Erbitux® (cetuximab) can now be used in Japan in combination with chemotherapy in the 1st-line treatment for patients with epidermal growth factor receptor -expressing, curatively unresectable (inoperable), advanced or recurrent colorectal cancer carrying the KRAS wildtype gene.

29 Mar 2010

TB-causing bacteria can hijack fat metabolism to drive progression of the disease

The factors instrumental in triggering latent tuberculosis infection to progress into active disease have long remained elusive to researchers. New insight into the mystery is provided by Professor David Russell, speaking at the Society for General Microbiology's spring meeting in Edinburgh today. His work could help develop innovative strategies for treating the disease.

29 Mar 2010

Norovirus outbreak associated with oysters: FDA and Mississippi, Louisiana public health agencies issue warning

The U.S. Food and Drug Administration is working with state health officials from Mississippi and Louisiana to notify consumers, food service operators and retailers nationwide about an outbreak of norovirus associated with oysters recently harvested from an area near Port Sulphur, La. known as Area 7. The oysters were sold or distributed nationwide.

27 Mar 2010

Biophotonics: Light to cure disease

Biophotonics, or photomedicine, is a relatively unknown discipline, though it has existed for years now. You may have even benefited from it without realizing it. Some of the greatest advances of this field can be found in applications for the areas of oncology, dermatology, ophthalmology, surgery and cardiology.

27 Mar 2010

Presence of PARP protein in tumours can help predict their response to chemotherapy

The presence of the protein poly polymerase in tumours can help predict their response to chemotherapy, a German scientist will tell the seventh European Breast Cancer Conference in Barcelona tomorrow (Saturday 27 March).

27 Mar 2010

Studies shed light on treatment options for women carrying BRCA1 and BRCA2 genetic mutations

Two studies to be presented at the seventh European Breast Cancer Conference (EBCC7) in Barcelona today (Friday) and tomorrow (Saturday), shed light on the treatment options facing women carrying the BRCA1 and BRCA2 genetic mutations which predispose them to breast cancer.

27 Mar 2010

Genome sequencing of tumors biopsied from women with invasive breast cancer

Tumors biopsied from women with invasive breast cancer are having their genomes sequenced in an attempt to develop a DNA profile that one day may identify ahead of time the patients who will most likely respond to chemotherapy with an aromatase inhibitor. Aromatase inhibitors are a class of chemotherapeutic agents that block the production of estrogen in postmenopausal women.

27 Mar 2010

Sutter Solano Cancer Center earns three-year accreditation from ACOS

Sutter Solano Cancer Center has earned a three-year accreditation with six commendations from the Commission on Cancer of the American College of Surgeons. ACOS approval is awarded to centers that have voluntarily committed to providing the highest level of quality cancer care and undergo regular evaluations and reviews of their performance.

27 Mar 2010

Survival improving in patients with HER2 positive metastatic breast cancer

Barcelona, Spain: Trends indicate that survival is improving in patients with metastatic breast cancer, especially in those patients whose tumours are described as being HER2 (human epidermal growth factor receptor-2) positive, a surgical oncologist will say today at the seventh European Breast Cancer Conference (EBCC7).

26 Mar 2010

Study finds 15-year outcomes of BCT and mastectomy similar

26 Mar 2010

Presence of protein PARP in tumours may help predict response to chemotherapy

The presence of the protein poly (ADP-ribose) polymerase (PARP) in tumours can help predict their response to chemotherapy, a German scientist will tell the seventh European Breast Cancer Conference (EBCC7) in Barcelona tomorrow (Saturday 27 March). Professor Gunter von Minckwitz, from the German Breast Group Forschungs GmBH, Neu-Isenburg, says that, contrary to current belief that PARP is associated with a limited number of tumours, he and his team found for the first time that PARP expression exists across all breast cancer subtypes, and that such tumours were highly sensitive to chemotherapy.

26 Mar 2010

Survival rate is improving in HER2 positive breast cancer patients

Trends indicate that survival is improving in patients with metastatic breast cancer, especially in those patients whose tumours are described as being HER2 (human epidermal growth factor receptor-2) positive, a surgical oncologist will say today (Friday 26 March) at the seventh European Breast Cancer Conference.

26 Mar 2010

Abnormality on chromosome 17 helps detect breast cancer tumour's response to anthracyclines

British researchers have discovered a new way of detecting which breast cancer patients are going to respond best to chemotherapy that includes anthracycline antibiotics. The study has found that an abnormality on chromosome 17, called CEP17, is not only associated with a worse outcome for patients, but also that its presence is a highly significant indicator that the tumour will respond to anthracyclines. The research will be presented at the European Breast Cancer Conference (EBCC7) Thursday 25th March.

26 Mar 2010

Informing young women surviving breast cancer about opportunities to have children

At a time when more and more young women are surviving breast cancer and delaying childbirth, it is important to take their needs and wishes about their future fertility into consideration when deciding on treatment, the seventh European Breast Cancer Conference (EBCC7) in Barcelona will hear today.

26 Mar 2010

False perception of increased risk induces women with breast cancer have prophylactic mastectomies

Women who have been diagnosed with breast cancer believe the risk of the disease occurring in their unaffected breast is as much as ten times higher than it actually is. As a result, they are choosing to have prophylactic mastectomies based on a false perception of increased risk, according to new research.

26 Mar 2010

Adjuvant systemic must be considered for treatment of primary breast cancer and recurrence

Recurrence of breast cancer in the same area as the original tumour remains the strongest, independent prognostic factor for subsequent metastasis and death, even for patients who have been free of disease for a very long time, according to research presented today (Wednesday) at the seventh European Breast Cancer Conference (EBCC7).

26 Mar 2010

Bevacizumab/paclitaxel/carboplatin regimen attains gold-standard status for treatment of non-small-cell lung cancer

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the bevacizumab (Genentech/Roche/Chugai's Avastin)/paclitaxel (Bristol-Myers Squibb's Taxol, generics)/carboplatin (Bristol-Myers Squibb's Paraplatin, generics) regimen will remain Decision Resources' proprietary clinical gold standard for the treatment of advanced non-small-cell lung cancer through 2018.

26 Mar 2010

Pregnant breast cancer patients can receive chemotherapy without endangering baby health

Women who discover they have breast cancer while they are pregnant can be treated with chemotherapy without endangering the health of their unborn baby, according to research to be presented at the seventh European Breast Cancer Conference (EBCC7) in Barcelona today (Friday).

26 Mar 2010

Novelos Therapeutics commences enrollment in Phase 2 trial of NOV-205 for chronic hepatitis C

Novelos Therapeutics, Inc., a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, today announced that it has enrolled the first patient in a U.S. Phase 2 trial evaluating NOV-205 as monotherapy in up to 40 chronic hepatitis C genotype 1 patients who previously failed treatment with pegylated interferon plus ribavirin.

26 Mar 2010

AVASTIN receives Health Canada approval for patients with GBM

Roche Canada announced today that Health Canada has approved AVASTIN(R) (bevacizumab), as a single agent, for the treatment of patients with glioblastoma multiforme, the most aggressive primary malignant brain tumour, after relapse or disease progression, following prior therapy.

26 Mar 2010

Chemotherapy News and Research

Latest Chemotherapy News and Research

Erbitux can now be used in Japan as 1st-line treatment for mCRC: Merck Serono

TB-causing bacteria can hijack fat metabolism to drive progression of the disease

Norovirus outbreak associated with oysters: FDA and Mississippi, Louisiana public health agencies issue warning

Biophotonics: Light to cure disease

Presence of PARP protein in tumours can help predict their response to chemotherapy

Studies shed light on treatment options for women carrying BRCA1 and BRCA2 genetic mutations

Genome sequencing of tumors biopsied from women with invasive breast cancer

Sutter Solano Cancer Center earns three-year accreditation from ACOS

Survival improving in patients with HER2 positive metastatic breast cancer

Study finds 15-year outcomes of BCT and mastectomy similar

Presence of protein PARP in tumours may help predict response to chemotherapy

Survival rate is improving in HER2 positive breast cancer patients

Abnormality on chromosome 17 helps detect breast cancer tumour's response to anthracyclines

Informing young women surviving breast cancer about opportunities to have children

False perception of increased risk induces women with breast cancer have prophylactic mastectomies

Adjuvant systemic must be considered for treatment of primary breast cancer and recurrence

Bevacizumab/paclitaxel/carboplatin regimen attains gold-standard status for treatment of non-small-cell lung cancer

Pregnant breast cancer patients can receive chemotherapy without endangering baby health

Novelos Therapeutics commences enrollment in Phase 2 trial of NOV-205 for chronic hepatitis C

AVASTIN receives Health Canada approval for patients with GBM

Cancer Research - Second Edition eBook

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Chemotherapy News and Research

Latest Chemotherapy News and Research

Cancer Research - Second Edition eBook

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Newsletters you may be interested in